Search alternatives:
web decrease » we decrease (Expand Search), teer decrease (Expand Search), step decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a web » _ web (Expand Search)
web decrease » we decrease (Expand Search), teer decrease (Expand Search), step decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a web » _ web (Expand Search)
-
6521
-
6522
-
6523
Coral reef resilience differs among islands within the Gulf of Mannar, southeast India, following successive coral bleaching events
Published 2021“…Overall, between 2005 and 2017 reefs had a simultaneous decrease in relative coral cover (avg. = ? …”
Get full text
Get full text
-
6524
PPM1A is critical for proliferation of intestinal organoids.
Published 2021“…A dramatic lower number of de novo crypts (D, top panel) and the decreased size of organoids (D, bottom panel) were seen in organoids from PPM1A KO mice, with roughly 50 intestine organoids each group examined. …”
-
6525
Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity
Published 2018“…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
-
6526
Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity
Published 2018“…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
-
6527
Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity
Published 2018“…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
-
6528
Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity
Published 2018“…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
-
6529
Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity
Published 2018“…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
-
6530
Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity
Published 2018“…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
-
6531
Image_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF
Published 2018“…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
-
6532
Image_2_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF
Published 2018“…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
-
6533
Table_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.DOCX
Published 2018“…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
-
6534
Image_2_Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.jpeg
Published 2023“…Further subgroup analyses indicated that SGLT2i presented more advantages on longer treatment duration and more serious steatosis in decreasing LSM. For CAP, SGLT2i exhibited a clear advantage in subgroup analyses of longer treatment duration, younger people, dapagliflozin, worse fibrosis, and steatosis.…”
-
6535
Supplementary Material for: Efficacy of Huanglian Jiedu Decoction for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Published 2024“…This meta-analysis aims to determine the efficacy and safety of HJD in the treatment of T2DM. Methods: A systematic review was conducted across six databases including PubMed, Embase, Cochrane, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang, from their inception to August 24, 2023. …”
-
6536
Table_1_Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.docx
Published 2023“…Further subgroup analyses indicated that SGLT2i presented more advantages on longer treatment duration and more serious steatosis in decreasing LSM. For CAP, SGLT2i exhibited a clear advantage in subgroup analyses of longer treatment duration, younger people, dapagliflozin, worse fibrosis, and steatosis.…”
-
6537
Image_1_Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.jpeg
Published 2023“…Further subgroup analyses indicated that SGLT2i presented more advantages on longer treatment duration and more serious steatosis in decreasing LSM. For CAP, SGLT2i exhibited a clear advantage in subgroup analyses of longer treatment duration, younger people, dapagliflozin, worse fibrosis, and steatosis.…”
-
6538
-
6539
-
6540